CURIA Global Inc.

Custom API Manufacturing, Fermentation, Finished Dosage Form, High Potency, Lipid Nanoparticle, Rare / Orphan, Stability & Release Testing, Sterile Fill Finish, APIs & Intermediates, Fine Chemicals

Discovery - Biology, Lead Optimization, Libraries, Synthetic & Medicinal ChemistryDevelopment - Chemical Process R&D, Fermentation, Formulation Development, High Potency, Kilo Lab & Small Scale Manufacturing, Lipid Nanoparticle, Method Development/Material Science, Rare/Orphan, Separation Scien...

The $35 million investment will more than double the site’s batch-size scaling and product output.

Curia Development

Acquisition will add West Coast coverage to the CDMO's East Coast and European capabilities and enhance its biologics formulation development and fill-finish network

API Product Catalog

With CPHI North America fast approaching, we ask Karen Flynn (President, Biologics & Chief Commercial Officer, at Catalent), Hamilton Lenox (Senior Vice President of Business Development, Sales & Marketing, at LGM Pharma), and Mike Kleppinger, Chief Commercial Officer, at AMRI) to weigh in on strategies the industry can use to build supply chain resiliency which ensure uninterrupted access to medicines

From early discovery and development through manufacturing and commercialization, Curia’s suite of custom solutions allows us to tailor every engagement to your precise needs, whether that’s an independent project or an opportunity that spans the drug development lifecycle.

Drawing from diverse branches of chemistry, biology, physics, engineering and pharmaceutical sciences, Curia provides scientific expertise and state-of-the-art technology to solve your most complex challenges and deliver integrated pharmaceutical drug development programs from preclinical to commercial. We provide development services at locations within the United States and Europe. Our process development services are strategically located to deliver timely execution through convenient local points of contact.

Curia offers comprehensive development and manufacturing services to meet needs through the entire life cycle of your sterile drug product. Leverage our in-depth expertise and capabilities at any scale, from early clinical through large-scale commercial.

Curia API Catalog

From early discovery and development through manufacturing and commercialization, Curia can tailor a program to fit your needs.

Curia End to End Solutions

Curia is one of the largest independent developers and suppliers of APIs to the life sciences industry. Our complete suite of capabilities supports the chemical development and cGMP manufacture of complex APIs,including but not limited to potent and cytotoxic compounds and controlled substances. With world-class facilities in North America, Europe and Asia,we provide the scale and technology to serve your needs from development to manufacturing, for small to commercial-sized batches. Curia has a track record of quality and compliance with the FDA, AIFA, PMDA and other regulatory agencies and more than 550 API DMPs filed worldwide.

Curia’s comprehensive drug discovery services include biology,synthetic and medicinal chemistry, DMPK and bioanalytical services that span the continuum from hit-to-lead identification through candidate selection. Our solutions offer reduced compound testing cycle times, efficient internal sample transfer and rapid, data-driven decision making. Capitalize on the value of our integrated drug discovery centers of excellence that combine scientific expertise and leading-edge technology to accelerate innovation.

Fine Chemicals Catalog